Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life

Jan 13 2003

• By The Pink Sheet

Related Content

PhRMA Wants Amended ANDAs To Trigger 30-Month Stays

Jan 06 2003

BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending

Oct 22 2001

Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents

Nov 12 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window